Therefore, we may suppose that the down-regulation of TF in melanoma cells could be responsible of the decrease levels of TG and d-dimer observed in patients with an efficient therapeutic response to BRAF inhibitors; on the contrary, in patients who respond < 85% or do not respond high levels of coagulation markers could be maintained since BRAF inhibitors may also fail to down-regulate TF in melanoma cells. The gene discussed is TF; the disease is melanoma.